MDST Medicsight

Medicsight Plc
26 November 2007


Press Release                                                   26 November 2007


                                 Medicsight PLC
                        ("Medicsight" or "the Company")


          Medicsight to present new data at major radiology conference


Medicsight PLC (AIM:MDST), industry leader in the development of Computer-Aided
Detection (CAD) and image analysis software which assists in the early detection
and diagnosis of disease, is pleased to announce that it will be presenting two
study abstracts at the annual meeting of the Radiological Society of North
America in Chicago 25-30 November. The RSNA meeting is the major radiological
event of the year. These presentations contain data from two company-sponsored
studies that highlight the beneficial role of CAD in the interpretation of
images from computerised tomography colonography (CTC) for the diagnosis of
early-stage colorectal cancer. Medicsight will be showcasing its CAD products at
both its partners' and its own exhibition areas. Medicsight's booth number at
RSNA is 6530.


                                    - ENDS -


For further information:

Medicsight PLC

David Sumner                                            Tel: +44 (0)20 7605 7950
                                                        www.medicsight.com
Collins Stewart Europe Limited

Tim Mickley                                             Tel: +44 (0)20 7523 8350
Jonny Sloan                                             Tel: +44 (0)20 7523 8302


Media enquiries:

Abchurch

Ashley Tapp                                            Tel: +44 (0) 20 7398 7700
ashley.tapp@abchurch-group.com
Stephanie Cuthbert                                     Tel: +44 (0) 20 7398 7700
stephanie.cuthbert@abchurch-group.com                     www.abchurch-group.com


On site trade press enquiries at RSNA:


Resolute

Beatrice Evangelista                                        Tel: +1 646 221 8299
Bea.Evangelista@resolutecommunications.com

Notes to editors

Medicsight PLC is a UK-based, research driven, leading developer of
computer-aided detection (CAD) and image analysis software for the medical
imaging market. The CAD software automatically highlights suspicious areas on
computerised tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early indicators of
disease. Medicsight's computer-aided detection (CAD) software has been validated
using one of the world's largest and most population diverse databases of
verified patient CT scan data.



About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as
Multi-Detector CT scanners, radiologists are facing a growing challenge in the
amount of detailed patient image data that they must review for each patient
examination. Some CT scan examinations generate as many as 1000 images per
patient. Review of this data by the radiologist is not only time-consuming but
also prone to error due to reader fatigue. CAD software can help the reviewing
radiologist by analysing the image data and automatically highlighting
suspicious regions of interest for closer inspection. Without CAD software some
potential abnormalities or areas of disease may be overlooked. This is critical
for diagnosis and the management of patient outcomes as early detection of
disease greatly increases the probability of successful treatment and a positive
therapeutic outcome.



About Medicsight's CAD software

Medicsight's ColonCADTM and LungCADTM software use an advanced CAD algorithm to
analyse CT scans of the colon and lung and automatically highlight suspicious
areas that may be indicators of disease. CAD may highlight areas easily
overlooked by the reviewing radiologist, such as small lesions or regions that
are hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.



Both CAD products seamlessly integrate with the advanced 3D visualisation
platforms of industry-leading imaging equipment partners. The integrated systems
provide sophisticated image viewing capabilities, including 3D reconstructed
image data, with the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease. This allows
clinical end users to perform either a 'second read', where CAD findings are
displayed to the user after completion of an initial review of the CT scan data,
or a 'concurrent read' where CAD findings are displayed during the user's
initial review of the original CT scan images.



Since inception, Medicsight has developed close and lasting relationships with
some of the world's foremost clinicians in product related areas. This provides
the Company with a wealth of clinical expertise and dedicated clinical research
to support ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research programmes
worldwide to develop the Company's comprehensive database of population diverse
verified patient CT scan data, thus allowing Medicsight's products to be
validated to the highest possible standards.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

NRAPUGBAGUPMGUW

Medicsight (LSE:MDST)
Historical Stock Chart
From Jun 2024 to Jul 2024

Medicsight (LSE:MDST)
Historical Stock Chart
From Jul 2023 to Jul 2024